Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

MRP of anti-cancer drugs to come down due to custom duty exemption and GST rate reduction

This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty

Krsnaa Diagnostics and Medikabazaar to invest Rs. 300+ crore to set up imaging centers

The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance

Biocon Biologics Global to raise funds through senior secured notes

The Notes shall not be offered or sold in India

Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL

Stable profits, low leverage to keep credit profiles comfortable

Aurobindo Pharma to acquire balance 49% stake in GLS Pharma

Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business

TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry

Coveris ramps up security label protection to tackle retail theft and supply-chain protection

Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur

Marksans Pharma Q1 FY25 revenue up 18%

Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%

Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024